The use of nutrient complexes in idiopathic male infertility associated with astenoand/or teratozoospermia: the search of predictors of treatment efficiency (preliminary results)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Nutrient complexes (dietary supplements) containing various vitamins, minerals, enzymes are popular substances for treatment of male infertility. However, the use of such complexes often does not lead to an improvement of ejaculate analysis and the restoration of fertility. Aim. To determine the predictors of efficiency of treatment with a complex of nutrients. Material and methods. An open, uncontrolled study which included 102 men from infertile couples aged 25-45 years with idiopathic asteno-, and/or teratozoospermia was conducted. All man received the complex of nutrients (4 capsules of 410 mg per day) containing L-arginine (720 mg), L-carnitine (240 mg), L-carnosine (92 mg), coenzyme Q10 (10 mg), glycyrrhetinic acid (6 mg), zinc (4,8 mg), vitamin Е (3,2 mg), vitamin А (0,36 mg), selenium (0,034 mg), which is from 12% to 80% of recommended level of daily intake for these substances. The ejaculate analysis was done in accordance to WHO recommendations, including the assessment of the production of reactive oxygen species (ROS). Results. After 3 months of treatment the proportion of sperm cells with progressive motility increased in 59% patients in the average by 4 % (р<0.05) due to an increase in the proportion of rapidly progressive sperms with grade “A” motility by 4 % (р<0,05) and a decrease in the proportion of non-progressive sperms (-2 %; р<0.05). The improvement was more often observed in patients with baseline lower sperm motility (р<0,05) and had phasic dependence on the ROS level. It was more pronounced (+24 % in relative values for motility “A”; р<0.05) in patients with moderate elevation of ROS level (2-4 IU), and insignificant at the normal (< 2 IU) and marked elevated (4-7 и >7 IU) ROS level. The standardized effect with an increase of ROS for motile spermatozoa of category A was 0.16, 0.47, 0.34 и 0.22, respectively, i.e., it was weak in all cases. The changes of sperm concentration and morphology were insignificant (р>0.05), but the improvement of sperm morphology was more often observed in patients with pathologic forms greater than 95 % (р<0.05). Conclusion. The increase in the proportion of sperm cells with progressive motility while taking nutrient complex had dependence on the baseline level of oxidative stress and it was more pronounced in patients with moderate elevation of ROS level. The further, more powerful studies to assess the influence of dietary of this supplement on the other ejaculate indicators.

Full Text

Restricted Access

About the authors

V. A Bozhedomov

Moscow Lomonosov State University; National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Health of Russia; Polyclinic №3 of the ADP of the RF

Email: vbojedomov@mail.ru
Dr.Med.Sci, professor, professor of Department of Urology and Andrology; chief researcher at the Department

A. A Kamalov

Moscow Lomonosov State University

Email: armais.kamalov@rambler.ru
Academician of the RAS, Dr.Med.Sci, Head of the Department of Urology and Andrology, Faculty of Fundamental Medicine, Director of the «University Hospital»

G. E Bozhedomova

Polyclinic №3 of the ADP of the RF

Email: bozhiedomova@bk.ru
medical technologist

V. I Kozlova

Polyclinic №3 of the ADP of the RF

Email: kovalentina@yandex.ru
biologist

R. A Kamarina

Polyclinic №3 of the ADP of the RF

Email: rimmafafa@mail.ru
doctor of clinical laboratory diagnostics

E. A Epanchintseva

Federal State Budget Scientific Institution «Federal Research Center of Fundamental and Translational Medicine

Email: epane@yandex.ru
Cand.Med.Sci., endocrinologist-andrologist at OOO “Novosibirsk Center of Reproductive medicine”, Group of companies “Mother and child”, chief researcher at the laboratory of endocrinology

References

  1. WHO Manual for the Standardized Investigation, Diagnosisand Management of the Infertile Male. Cambridge: Cambridge University Press. 2000;91.
  2. WHO laboratory manual for the examibation and processing of human semen. Fifth ed., WHO, 2010; 271.
  3. Божедомов В.А. Мужской фактор бездетного брака - пути решения проблемы. Урология. 2016;1, приложение 1:28-34
  4. Сухих Г.Т., Божедомов В.А. Мужское бесплодие. Практическое руководство для урологов и гинекологов, М.: Эксмо, 2009; 240 с ил.
  5. Andrology: Male Reproductive Health and Disfunction. 3rd. E. Nieschlag, H.M. Behre, S. Nieschlag (Ed.). 2010; 629.
  6. Male infertility / S.J. Parekattil, A. Agarwal (Ed.), 2012, Springer; 518.
  7. EAU Guidelines on Male Infertility / A. Jungwirth (Ed.). European Association of Urology. 2018; 42.
  8. Garg H., Kumar R. Empirical Drug Therapy for Idiopathic Male Infertility: What is the New Evidence? Urology. 2015 Dec;86(6):1065-1075.
  9. Ahmadi S., Bashiri R., Ghadiri-Anari A., Nadjarzadeh A. Antioxidant supplements and semen parameters: An evidence based review. Int J. Reprod Bio Med. 2016, 14 (12): 729-736.
  10. Fang F., Ni K., Shang J., Cai Y., Xiong C. The effect of antiestrogen administration on seminal parameters in men with idiopatic infertility: a systematic review and meta-analysis of randomized controlled trials. Abstracts of the 9th Congress of the European Academy of Andrology, 21-23 September. Rotterdam, Netherlands, 2016: 54.
  11. Calogero A., Condorelli R., Russo G., Vignera S. Conservative Nonhormonal Options for the Treatment of Male Infertility: Antibiotics, Anti-Inflammatory Drugs, and Antioxidants. Biomed Res Int. 2017; 2017:4650182. doi: 10.1155/2017/4650182. Epub 2017 Jan 9.
  12. Micic S., Latic N. Bojanic, Djordjevic D., Virmani A., Agarwal A. Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in randomizd, double blind, placebo study. Abstracts of the 32nd Annual Meeting of ESHRE, Helsinki, Finland, 3-6 July, 2016. P.151.
  13. Vaidya A., Ahmed A., Brunckhorst O., Yap T., Shabbir M. Nutritional supplements in idiopathic male infertility: A systematic review. Eur Urol Suppl 2018 17(2);e149.
  14. Ross C., Morriss A., Khairy M., Khalaf Y., Braude P., Coomarasamy A., et al. A systematic review of the effect of oral antioxidants on male infertility. Reprod Biomed Online. 2010, 20, 711-723.
  15. Akmal M., Qadri J., Al-Waili N., Thangal S., Haq A., Saloom K. Improvement in human semen quality after oral supplementation of vitamin C. J. Med Food. 2006 Fall; 9(3): 440-442.
  16. Cyrus A., Kabir A., Goodarzi D., Moghimi M. The effect of adjuvant vitamin C. after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. Int Braz J. Urol. 2015 Mar-Apr;41(2):230-238.
  17. Showell M., Mackenzie-Proctor R., Brown J., Yazdani A., Stankiewicz M., Hart R. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2014; (12):CD007411. doi: 10.1002/14651858.CD007411.pub3. Review.
  18. Божедомов В., Громенко Д., Ушакова И., Торопцева М., Галимов Ш., Сухих Г. Оксидативный стресс сперматозоидов в патогенезе мужского бесплодия. Урология. 2009; 2: 51-56
  19. Agarwal A., Deepinder F. Determination of seminal oxidants (reactive oxygen species) // In Infertility in the male. Fourth ed. Ed. L.I. Lipshults, S.S. Howards, C.S. Niederberger, 2009; 618-632.
  20. Tremellen K. Oxidative stress and male infertility-a clinical perspective. Hum. Reprod. Update, 2008, 14(3): 243-258.
  21. Aitken, R., Smith T., Jobling M., Baker M., De Iuliis G. Oxidative stress and male reproductive health. Asian J. Androl. 2014. 16: 31-38.
  22. Hughes E.G., Grantmyre J., Zini A. An integrated approach to male-factor subfertility: bridging the gap between fertility specialists trained in urology and gynaecology. J. Obstet Gynaecol Can. 2015 Mar;37(3):258-265.
  23. Scott R., MacPherson A., Yates R.W. The effect oforal selenium supplementation on human sperm motility. Br J. Urol. 1998; 82: 76-80.
  24. Keskes-Ammar L., Feki-Chakroun N., Rebai T., Sahnoun Z., Ghozzi H., Hammami S., et al. Sperm oxidative stress and the effect of an oral vitamin E. and selenium supplement on semen quality in infertile men. Arch Androl. 2003, 49, 83-94.
  25. Omu A., Al-Azemi M., Kehinde E., Anim J., Oriowo M., Mathew T. Indication of the mechanisms involved in improved sperm parameter by zinc therapy. Med Princ Pract. 2008; 17: 108-116.
  26. Galatioto G., Gravina G., Angelozzi G., Sacchetti A., Innominato P., Pace G. et al. May antioxidant therapy improve sperm parameter of men with persistent oligospermia after retrograde embolization for varicocele? World J. Urol. 2008; 26: 97-102.
  27. Rolf C., Cooper T., Yeung C., Nieschlag E. Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C. and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod 1999; 14: 1028-1033.
  28. Clifton G., Ellington J. Prospective Study of FertilAid Vitamin in Men with Low Sperm Quality. Poster Presented at: American Society of Andrology. Philadelphia, USA, 34th Annual Meeting; 4-7 April, 2009.
  29. Tremellen K., Miari G., Froiland D., Thompson J. A randomized control trial examining the effect an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Aust N. Z. J. Obstet Gynaecol., 2007; 47: 216-21.
  30. Micic S., Lalic N.,. Bojanic N., Djorjevic D., Virmani A., Agarwal A. DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Abstracts of the 9th Congress of the European Academy of Andrology, 21-23 September. Rotterdam, Netherlands, 2016: 56.
  31. Vessey W., McDonald C., Virmani A., Almeida P., Jayasena C., Ramsay J. Levels of reactive oxygen species (ROS) in the seminal plasma predicts the effectiveness of L-carnetine to improve sperm function in men with infertility. Abstracts of the 32nd Annual Meeting of ESHRE, Helsinki, Finland, 3 July - 6 July, 2016. Р.131.
  32. Krausz C., Escamilla A., Chianese C., Genetics of male infertility: from research to clinic. Reproduction. 2015; 150(5):159-174.
  33. Sperm chromatin: biological and clinical application in male infertility and assisted reproduction /A. Zini, A. Agarwal (Ed.), 2011, Springer, 512.
  34. Камалов А.А., Абоян И.А., Ситдыкова М.Э. и соавт. Применение биологически активного комплекса Андродоз® у пациентов с патоспермией и иммунологическим фактором инфертильности. Результаты мультицентрового клинического исследования. Фарматека. 2014; 4: 29-40
  35. Алчинбаев М.К., Медеубеков У.Ш., Хусаинов Т.Э. и соавт. Новые подходы к лечению патоспермиию. Урология, 2013, 2: 46-49
  36. Дендеберов Е., Виноградов И. Опыт применения биокомплекса АндроДоз для фертилизации больных с идиопатической патоспермией. Эффективная фармакотерапия, № 47, 2014. (Урология и нефрология № 4). С. 2-3
  37. Проскурин А., Голубкин Е., Поливин П., Казарян Э. Сравнительная оценка эффективности комплексной терапии идиопатического бесплодия. Проблемы репродукции 2013; 6: 65-66
  38. Неймарк А., Клепикова И., Неймарк Б., и соавт. Применение препарата АндроДоз у мужчин с нарушением фертильности. Андрология и генитальная хирургия 2013, 4: 44-52

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies